The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public–private partnerships for the development of new strategies to tackle antibiotic resistanceTomislav Kostyanev, Herman Goossens, Marc J. M. Bonten et al.|Journal of Antimicrobial Chemotherapy|2015Cited by 129
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trialJean Chastre, Tomas Hruby, Yuling Wu et al.|Critical Care|2022Cited by 93
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trialBruno François, Alain Lepape, Hasan S. Jafri et al.|The Lancet Infectious Diseases|2021Cited by 88
Alternatives to antibioticsBruno François, Marc J. M. Bonten, Hasan S. Jafri|Intensive Care Medicine|2016Cited by 42
The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public–Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia: Table 1.Bruno François, Hasan S. Jafri, Jean Chastre et al.|Clinical Infectious Diseases|2016Cited by 26